Dechra Pharmaceuticals

Dechra Veterinary Products acquires Dermapet; Strengthens Worldwide Dermatological Product Portfolio

OVERLAND PARK, KS, OCTOBER 22, 2010 – Dechra Veterinary Products announces it has completed the acquisition of Dermapet’s veterinary business. 

Dermapet, located in Potomac, MD, was established in 1991 by Dr. Steve Melman and has grown into a leading U.S. topical dermatology company.   

“We are excited to have acquired Dermapet and are extremely motivated to further strengthen our relationships with veterinary dermatologists, corporate hospitals, general practitioners and our distribution partners,” said Mike Eldred, President of U.S. Operations.  “Dermapet’s high quality all-natural dermatological product line is a perfect fit with our regulated dermatology products; Animax, Muricin and Vetromax. 

With additional investment in product development and marketing initiatives, I am confident Dechra will soon be recognized as a leader in the worldwide veterinary dermatology market segment.”   

Dr. Steve Melman, former President/CEO of Dermapet states, “After various meetings with Dechra, I knew immediately they were the best partner to take Dermapet to the next level.  Dechra has an impressive sales force, knowledge of the industry and solid relationships with many of the key influencers which will ensure future success.”

Dechra Veterinary Products, located in Overland Park, Kansas is the U.S. sales and marketing division of Dechra Pharmaceuticals PLC, a UK listed company dedicated to the animal healthcare market. Dechra Veterinary Products promotes and sells Vetoryl® (trilostane), Felimazole® (methimazole) and high quality veterinary approved dermatologic and ophthalmic products to veterinarians. 

For more information, please visit or call 866-933-2472.


  • AT
  • CZ
  • DK
  • FI
  • FR
  • DE
  • NL
  • IE
  • NO
  • ES
  • SE
  • UK
  • US
  • Global

22 October 2010